TIAPINE 100 Tablet: Each film coated tablet contains Quetiapine Fumarate INN equivalent to Quetiapine 100 mg.
TIAPINE 25 Tablet: Each film coated tablet contains Quetiapine Fumarate INN equivalent to Quetiapine 25 mg.
Quetiapine Fumarate is an atypical antipsychotic agent. Quetiapine Fumarate is an antagonist at multiple
neurotransmitter receptors in the brain: serotonin 5HT1A and 5HT2, dopamine D1 and D2, histamine H1 and
adrenergic α1 and α2 receptors. Quetiapine Fumarate has no appreciable affinity at cholinergic muscarinic
and benzodiazepine receptors. The efficacy of Quetiapine Fumarate in schizophrenia is mediated through a
combination of dopamine (D2) and serotonin (5HT2) receptor antagonism. Quetiapine’s antagonism of
histamine H1 receptors causes somnolence and antagonism of adrenergic α1 receptors causes orthostatic
Quetiapine Fumarate is rapidly absorbed after oral administration, reaching peak plasma concentrations in
1.5 hours. The tablet formulation is 100% bioavailable relative to solution. The bioavailability of Quetiapine
Fumarate is marginally affected by administration with food. Quetiapine Fumarate is widely distributed
throughout the body. It is 83% bound to plasma proteins at therapeutic concentrations. Approximately 73%
and 20% of the dose was recovered in the urine and faces, respectively. Elimination of Quetiapine Fumarate
is mainly via hepatic metabolism with a mean terminal half-life of about 6 hours within the proposed clinical
dose range. Steady-state concentrations are expected to be achieved within two days of dosing.
◊ Acute manic episodes associated with bipolar I disorder, as monotherapy or adjunct therapy to
The very commonly reported side effects with Quetiapine is dizziness; commonly reported side effects are
somnolence, leucopenia, tachycardia, dry mouth, mild asthenia, constipation, orthostatic hypotension,
dyspepsia, syncope, peripheral edema, weight gain, elevation in serum transaminases and rhinitis.